Treatment for COVID 19 and Long COVID with Low Dose Naltrexone (LDN) covered in the LDN Book 3
I'm Angus Dalgleish, Professor of Oncology at Saint George's University of London and Principal of the Institute of Cancer Vaccines and Immunotherapy. Giving patients Low Dose Naltrexone who've suffered long haul COVID for over a year has led to dramatic improvements in their symptoms. Sometimes it really is dramatic in two or three weeks, other times, it takes slightly longer, and we know that the link is real because if you withdraw the Low Dose Naltrexone too early, they relapse and reintroduce it. They benefit again, and I am surprised it has not become a standard of care.
I'm Dr. Sarah Zielsdorff, an internist microbiologist. COVID19 often causes the reactivation of dormant viruses, including herpes simplex virus 1 and 2, Epstein Barr virus, Varicella Zoster, and Parvovirus B19. Injury to gut and pulmonary tissues leads to polymicrobial sepsis, and hyperactivation of toll-like receptors leads to cytokine storm. Attenuating toll-like receptor 4 is central for treating COVID. The targets are the gut and lung tissues. LDN is the most well-studied and well-established attenuator of multiple toll-like receptors.